COPENHAGEN: Danish prescribed drugs heavyweight Novo Nordisk stated Tuesday (Jul 21) it’s suing arch US rival Eli Lilly over “false and materially deceptive” adverts for its competing weight-loss and anti-diabetes therapies.
The Danish maker of Wegovy and Ozempic complained that the US group – which makes rival weight-loss therapies Zepbound and Mounjaro – “deliberately chosen outdated research” that in contrast Lilly’s highest doses in opposition to decrease doses of Novo Nordisk’s medicines.
The US group’s advertisements “deceptively (offered) these outcomes as proof of broad, product-level superiority whereas burying or omitting vital scientific context,” the Danish group stated.
Novo Nordisk has developed a molecule known as semaglutide, whereas Eli Lilly developed rival molecule tirzepatide.
The competing medication are a monetary windfall for every of the pharmaceutical giants.
“As new and more practical therapy choices develop into out there, individuals deserve correct data that displays the most recent scientific proof and helps them make knowledgeable care choices,” stated Novo Nordisk’s common counsel, John F. Kuckelman.
“Healthcare corporations have a accountability to maintain their public claims correct and present – ineffective, fine-print disclaimers don’t repair the deceptive impression created by main nationwide campaigns.”
The goal of the Danish group’s wrath is an promoting marketing campaign that was “aired throughout current, broadly seen world sporting broadcasts and on TikTok and Fb, inflicting widespread confusion,” it stated.
